Back to Archived News
Cytori Receives U.S. Patent Allowance for Key Commercial Products
Wednesday, April 01, 2009
San Diego, CA -- Cytori Therapeutics, Inc. (Nasdaq: CYTX) received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent application that protects key therapeutic methods for its breast and soft tissue reconstruction products. This patent will protect Cytori's existing and future products when sold in the U.S.
Cytori currently sells the Celution 800/CRS System, which creates adipose tissue derived stem and regenerative cell enhanced autologous fat grafts, in many countries around the world. The allowed patent will protect alternative configurations of the Celution 800/CRS System, including smaller versions with accelerated processing times tailored to procedures such as the treatment of stress urinary incontinence.
This patent allowance expands on the Company's previously issued core device patent, U.S. Patent No. 7,390,484, as well as the Company's previously issued U.S. Patent No. 7,429,488 relating to automated methods of creating cell enhanced fat grafts.
Cytori's intellectual property portfolio related to the devices, methods and uses of adipose-derived stem and regenerative cells includes ten U.S. and International patents and numerous applications worldwide.
Cytori Therapeutics, Inc. manufactures, develops, and internationally commercializes innovative medical technologies, which allow physicians to practice regenerative medicine. Commercial activities are currently focused on marketing the Celution cell processing system and related family of products across three areas. The first is cosmetic and reconstructive surgery in Europe and Asia-Pacific. The second is to fulfill the demand among physicians in Europe and Asia Pacific for access to clinical grade stem and regenerative cells. The third is to market the Celution-based StemSource Cell Bank worldwide to hospitals and tissue banks so they can in turn offer patients the opportunity to cryopreserve their own adipose-derive stem and regenerative cells. The Company's development pipeline includes applications for cardiovascular disease, renal failure, orthopedic damage, gastrointestinal disorders, and pelvic health conditions, among others. www.cytoritx.com
Cautionary Statement Regarding Forward-Looking Statements
This press release includes forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks and uncertainties include our history of operating losses, the need for further financing, inherent risk and uncertainty in the protection intellectual property rights, regulatory uncertainties regarding the collection and results of, clinical data, dependence on third party performance, and other risks and uncertainties described under the "Risk Factors" in Cytori's Securities and Exchange Commission Filings, including its annual report on Form 10-K for the year ended December 31, 2008. Cytori assumes no responsibility to update or revise any forward-looking statements contained in this press release to reflect events, trends or circumstances after the date of this press release.
Back to Archived News